Quick Answer
VERTEX PHARMACEUTICALS INC / MA reported Total Revenue of $12.00 billion for the year ending 2025.
- VERTEX PHARMACEUTICALS INC / MA showed an increase of +8.9% in Total Revenue from 2024 to 2025.
- This data is from VERTEX PHARMACEUTICALS INC / MA's annual report (Form 10-K), filed with the SEC on February 13, 2026.
- XBRL data for this metric is available from 2008 to 2025 (20 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2014: $118.45 million | Q2 2014: $138.42 million | Q3 2014: $178.99 million | Q4 2014: $144.56 million | Q1 2015: $138.51 million | Q2 2015: $166.08 million | Q3 2015: $309.82 million | Q4 2015: $417.94 million | Q1 2016: $398.08 million | Q2 2016: $431.61 million | Q3 2016: $413.78 million | Q4 2016: $458.71 million | Q1 2017: $714.72 million | Q1 2017: $714.72 million | Q2 2017: $544.14 million | Q2 2017: $544.14 million | Q3 2017: $578.17 million | Q3 2017: $578.17 million | Q4 2017: $651.63 million | Q4 2017: $651.63 million | Q1 2018: $640.80 million | Q1 2018: $640.80 million | Q2 2018: $752.16 million | Q3 2018: $784.54 million | Q4 2018: $870.11 million | Q1 2019: $858.44 million | Q2 2019: $941.29 million | Q3 2019: $949.83 million | Q4 2019: $1.41 billion | Q1 2020: $1.52 billion | Q2 2020: $1.52 billion | Q3 2020: $1.54 billion | Q4 2020: $1.63 billion | Q1 2021: $1.72 billion | Q2 2021: $1.79 billion | Q3 2021: $1.98 billion | Q1 2022: $2.10 billion | Q2 2022: $2.20 billion | Q3 2022: $2.33 billion | Q1 2023: $2.37 billion | Q2 2023: $2.49 billion | Q3 2023: $2.48 billion | Q1 2024: $2.69 billion | Q2 2024: $2.65 billion | Q3 2024: $2.77 billion | Q1 2025: $2.77 billion | Q2 2025: $2.96 billion | Q3 2025: $3.08 billion.
- Over the full 20 years of available data (2008 to 2025), VERTEX PHARMACEUTICALS INC / MA's Total Revenue has grown by 6,738.2%.
- Historical annual values: Fiscal year 2025: $12.00 billion | Fiscal year 2024: $11.02 billion | Fiscal year 2023: $9.87 billion | Fiscal year 2022: $8.93 billion | Fiscal year 2021: $7.57 billion | Fiscal year 2020: $6.21 billion | Fiscal year 2019: $4.16 billion | Fiscal year 2018: $3.05 billion | Fiscal year 2017: $2.49 billion | Fiscal year 2017: $2.49 billion | Fiscal year 2016: $1.70 billion | Fiscal year 2016: $1.70 billion | Fiscal year 2015: $1.03 billion | Fiscal year 2014: $580.42 million | Fiscal year 2013: $1.21 billion | Fiscal year 2012: $1.53 billion | Fiscal year 2011: $1.41 billion | Fiscal year 2010: $143.37 million | Fiscal year 2009: $101.89 million | Fiscal year 2008: $175.50 million.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: